Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: The LIFE study

Blood Pressure

Volumn 13, Issue 6, 2004, Pages 376-384

  Reims, Henrik M ^a   Oparil, Suzanne ^b   Kjeldsen, Sverre E ^a,c   Devereux, Richard B ^d   Julius, Stevo ^c   Brady, William E ^e   Fyhrquist, Frej ^f   Ibsen, Hans ^g   Lindholm, Lars H ^h   Omvik, Per ⁱ   Wedel, Hans ^j   Beevers, Gareth ^k   De Faire, Ulf ^l   Kristianson, Krister ^m   Lederballe Pedersen, Ole ⁿ   Nieminen, Markku S ^f   Dahlöf, Björn ^o  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

^d WEILL CORNELL MEDICAL CENTER   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

^f HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^g GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^h UMEÅ UNIVERSITY HOSPITAL   (Sweden)

ⁱ HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^j NORDIC SCHOOL OF PUBLIC HEALTH   (Sweden)

^k CITY HOSPITAL   (United Kingdom)

^l KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^m Merck Research Laboratories Scandinavia   (Sweden)

ⁿ VIBORG HOSPITAL   (Denmark)

^o SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

Atenolol; Cardiovascular disease; Hypertension; LIFE study; Losartan; Smoking

Indexed keywords

ATENOLOL; LOSARTAN;

ADULT; AGE; AGED; ALCOHOL CONSUMPTION; ARTICLE; ASIAN; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUCASIAN; CIGARETTE SMOKING; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; ECHOCARDIOGRAPHY; EXERCISE; FEMALE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HISPANIC; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEGRO; PRIORITY JOURNAL; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK REDUCTION; SEX DIFFERENCE; SMOKING HABIT; STROKE; TREATMENT OUTCOME;

AGED; ANALYSIS OF VARIANCE; ATENOLOL; CARDIOVASCULAR DISEASES; CEREBROVASCULAR ACCIDENT; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; INCIDENCE; LOSARTAN; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; REGRESSION ANALYSIS; SMOKING;

EID: 19944398725     PISSN: 08037051     EISSN: None     Source Type: Journal    
DOI: 10.1080/08037050410016483     Document Type: Article

References (33)

1. Kannel WB, Higgins M. Smoking and hypertension as predictors of cardiovascular risk in population studies. J Hypertens 1990; 8 Suppl 5: S3-8.
2. Shinton R, Beevers G. Meta-analysis of relation between cigarette smoking and stroke. Br Med J 1989; 298: 789-94.
3. Goldstein LB, Adams R, Becker K, et al. Primary prevention of ischemic stroke: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Circulation 2001; 103: 163-82.
4. Ezzati M, Lopez AD, Rodgers A, et al. Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet 2002; 360: 1347-60.
5. Winniford MD. Smoking and cardiovascular function. J Hypertens 1990; 8 Suppl 5: S17-23.
6. Craig WY, Palomäki GE, Haddow JE. Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of published data. Br Med J 1989; 298: 784-8.
7. Khalili P, Nilsson PM, Nilsson JA, et al. Smoking as a modifier of the systolic blood pressure-induced risk of cardiovascular events and mortality: a population-based prospective study of middle-aged men. J Hypertens 2002; 20: 1759-64.
8. Dahlöf B, Devereux R, de Faire U, et al. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group. Am J Hypertens 1997; 10: 705-13.
9. Dahlöf B, Devereux RB, Julius S, et al. Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension. Hypertension 1998; 32: 989-97.
10. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
11. Okin PM, Devereux RB, Jern S, et al. Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan intervention for endpoint reduction (LIFE) in hypertension study. The Life Study Investigators. Hypertension 2000; 36: 766-73.
12. The IPPPSH Collaborative Group. Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). J Hypertens 1985; 3: 379-92.
13. Media Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. Br Med J 1985; 291: 97-104.
14. Wilhelmsen L, Berglund G, Elmfeldt D, et al. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens 1987; 5: 561-72.
15. Wikstrand J, Warnold I, Olsson G, et al. G. Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. JAMA 1988; 259: 1976-82.
16. Tuomilehto J, Wikstrand J, Olsson G, et al. Decreased coronary heart disease in hypertensive smokers. Mortality results from the MAPHY study. Hypertension 1989; 13: 773-80.
17. Trap-Jensen J, Carlsen JE, Svendsen TL, et al. Cardiovascular and adrenergic effects of cigarette smoking during immediate non-selective and selective beta adrenoceptor blockade in humans. Eur J Clin Invest 1979; 9: 181-3.
18. Tangø M, Krogsgaard AR, Trap-Jensen J, et al. Haemodynamic effects of cigarette smoking before and during long-term non-selective and selective beta-adrenergic blockade in patients with arterial hypertension. Acta Med Scand Suppl 1985; 693: 111-14.
19. Cryer PE, Haymond MW, Santiago JV, et al. Norepinephrine and epinephrine release and adrenergic mediation of smoking-associated hemodynamic and metabolic events. N Engl J Med 1976; 295: 573-7.
20. Groppelli A, Giorgi DM, Omboni S, et al. Persistent blood pressure increase induced by heavy smoking. J Hypertens 1992; 10: 495-9.
21. Omvik P. How smoking affects blood pressure. Blood Press 1996; 5: 71-7.
22. Verdecchia P, Schillaci G, Borgioni C, et al. Cigarette smoking, ambulatory blood pressure and cardiac hypertrophy in essential hypertension. J Hypertens 1995; 13: 1209-15.
23. Wachtell K, Olsen MH, Dahlöf B, et al. Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. J Hypertens 2002; 20: 405-12.
24. Derby CA, Lapane KL, Hume AL, et al. Is cigarette smoking an effect modifier of the relation between antihypertensive therapy and blood lipids? Epidemiology 1997; 8: 48-54.
25. Wannamethee SG, Shaper AG, Perry IJ. Smoking as a modifiable risk factor for type 2 diabetes in middle-aged men. Diabetes Care 2001; 24: 1590-5.
26. Lindholm LH, Ibsen H, Borch-Johnsen K, et al. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 2002; 20: 1879-86.
27. Puranik R, Celermajer DS. Smoking and endothelial function. Prog Cardiovasc Dis 2003; 45: 443-58.
28. Brasier AR, Recinos A 3rd,, Eledrisi MS. Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol 2002; 22: 1257-66.
29. Schiffrin EL, Park JB, Intengan HD, et al. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000; 101: 1653-9.
30. Zhang C, Hein TW, Wang W, et al. Divergent roles of angiotensin II AT1 and AT2 receptors in modulating coronary microvascular function. Circ Res 2003; 92: 322-9.
31. Krämer C, Sunkomat J, Witte J, et al. Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179. Circ Res 2002; 90: 770-6.
32. Rosenberg L, Kaufman DW, Helmrich SP, et al. The risk of myocardial infarction after quitting smoking in men under 55 years of age. N Engl J Med. 1985; 313: 1511-4.
33. Zanchetti A, Hansson L, Clement D, et al. Benefits and risks of more intensive blood pressure lowering in hypertensive patients of the HOT study with different risk profiles: does a J-shaped curve exist in smokers? J Hypertens 2003; 21: 797-804.